BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 19887890)

  • 1. Immunohistochemical study of matrix metalloproteinase 9 and tissue inhibitor of matrix metalloproteinase 1 in benign and malignant breast tissue--strong expression in intraductal carcinomas of the breast.
    Rahko E; Kauppila S; Pääkkö P; Blanco G; Apaja-Sarkkinen M; Talvensaari-Mattila A; Turpeenniemi-Hujanen T; Jukkola A
    Tumour Biol; 2009; 30(5-6):257-64. PubMed ID: 19887890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix-metalloproteinases 1, 2, and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridization study.
    Brummer O; Athar S; Riethdorf L; Löning T; Herbst H
    Virchows Arch; 1999 Dec; 435(6):566-73. PubMed ID: 10628798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen Receptor and Cytokeratin 5 Are Reliable Markers to Separate Usual Ductal Hyperplasia From Atypical Ductal Hyperplasia and Low-Grade Ductal Carcinoma In Situ.
    Martinez AP; Cohen C; Hanley KZ; Li XB
    Arch Pathol Lab Med; 2016 Jul; 140(7):686-9. PubMed ID: 27116088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
    Yang M; Xu SP; Ao QL
    Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of matrix metalloproteinases and their tissue inhibitors in ductal in situ carcinomas of the breast.
    Gonzalez LO; Corte MD; Vazquez J; Junquera S; Sanchez R; Viña A; Rodriguez JC; Lamelas ML; Vizoso F
    Histopathology; 2008 Oct; 53(4):403-15. PubMed ID: 18983606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence of chromosomal alterations in pure usual ductal hyperplasia as a breast carcinoma precursor.
    Xu S; Wei B; Zhang H; Qing M; Bu H
    Oncol Rep; 2008 Jun; 19(6):1469-75. PubMed ID: 18497952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Detection and clinical significance of Notch1 methylation in breast cancer and intraductal proliferative breast lesions].
    Zhang N; Sun ZZ; Li F; Cao YW; Zhao CX; Liang WH; Sun HP; Li HA; Fu XG
    Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):324-9. PubMed ID: 21756827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue distribution of major matrix metalloproteinases and their transcripts in human breast carcinomas.
    Lebeau A; Nerlich AG; Sauer U; Lichtinghagen R; Löhrs U
    Anticancer Res; 1999; 19(5B):4257-64. PubMed ID: 10628384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas.
    Nielsen BS; Rank F; López JM; Balbin M; Vizoso F; Lund LR; Danø K; López-Otín C
    Cancer Res; 2001 Oct; 61(19):7091-100. PubMed ID: 11585740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of cytokeratin expression in differential diagnosis of intraductal proliferative lesions of breast].
    Zhang JL; Zhang HY; Wei B; Lang ZQ; Bu H
    Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):316-9. PubMed ID: 15363314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of E-cadherin, beta-catenin, cathepsin D, gelatinases and their inhibitors in invasive ductal breast carcinomas.
    Zhang YG; DU J; Tian XX; Zhong YF; Fang WG
    Chin Med J (Engl); 2007 Sep; 120(18):1597-605. PubMed ID: 17908479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solid papillary ductal carcinoma in situ versus usual ductal hyperplasia in the breast: a potentially difficult distinction resolved by cytokeratin 5/6.
    Rabban JT; Koerner FC; Lerwill MF
    Hum Pathol; 2006 Jul; 37(7):787-93. PubMed ID: 16784976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression of matrix metalloproteinase-2, 9 and their inhibitor-TIMP 1,2 in human squamous cell carcinoma of uterine cervix].
    Zhou CY; Yao JF; Chen XD
    Ai Zheng; 2002 Jul; 21(7):735-9. PubMed ID: 12479097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas.
    Jones JL; Glynn P; Walker RA
    J Pathol; 1999 Oct; 189(2):161-8. PubMed ID: 10547569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endometase/matrilysin-2 in human breast ductal carcinoma in situ and its inhibition by tissue inhibitors of metalloproteinases-2 and -4: a putative role in the initiation of breast cancer invasion.
    Zhao YG; Xiao AZ; Park HI; Newcomer RG; Yan M; Man YG; Heffelfinger SC; Sang QX
    Cancer Res; 2004 Jan; 64(2):590-8. PubMed ID: 14744773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast carcinogenesis. Transition from hyperplasia to invasive lesions.
    Meteoglu I; Dikicioglu E; Erkus M; Culhaci N; Kacar F; Ozkara E; Uyar M
    Saudi Med J; 2005 Dec; 26(12):1889-96. PubMed ID: 16380768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression pattern and methylation of estrogen receptor α in breast intraductal proliferative lesions.
    Mao X; Qiao Z; Fan C; Guo A; Yu X; Jin F
    Oncol Rep; 2016 Oct; 36(4):1868-74. PubMed ID: 27498697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of ER, Ki-67 and cylinD1 in the pre-cancerous breast of Chinese patients.
    Zhou CJ; Zhang QH; Zhang TG; Sun SZ; Li H; Wang Y; Liu ZY
    Pathol Oncol Res; 2009 Jun; 15(2):153-8. PubMed ID: 18941930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical study of matrix metalloproteinases and their inhibitors in pure and mixed invasive and in situ ductal carcinomas of the breast.
    Gonzalez LO; Junquera S; del Casar JM; González L; Marín L; González-Reyes S; Andicoechea A; González-Fernández R; González JM; Pérez-Fernández R; Vizoso FJ
    Hum Pathol; 2010 Jul; 41(7):980-9. PubMed ID: 20236691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 nuclear accumulation and ERalpha expression in ductal hyperplasia of breast in a cohort of 215 Chinese women.
    Mao XY; Fan CF; Zheng HC; Wei J; Yao F; Jin F
    J Exp Clin Cancer Res; 2010 Aug; 29(1):112. PubMed ID: 20712900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.